Walleye Capital LLC Has $475,000 Stock Position in Evolus, Inc. $EOLS

Key Points

• Walleye Capital LLC significantly reduced its holdings in Evolus, Inc. by 86.8%, selling 259,450 shares and now owning approximately 0.06% of the company, valued at $475,000.
• Several institutional investors have increased their positions in Evolus, with AlphaQuest LLC acquiring a new stake worth approximately $39,000, while IFP Advisors Inc grew its holdings by 99.0%.
• Analysts have mixed views on Evolus, with target prices ranging from $18.00 to $22.00, and an overall average rating of "Moderate Buy" based on recent reports.

Walleye Capital LLC trimmed its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 86.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,498 shares of the company's stock after selling 259,450 shares during the period. Walleye Capital LLC owned about 0.06% of Evolus worth $475,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of EOLS. Nuveen LLC purchased a new stake in shares of Evolus during the first quarter worth $12,330,000. Millennium Management LLC raised its holdings in shares of Evolus by 29.1% during the fourth quarter. Millennium Management LLC now owns 1,368,423 shares of the company's stock worth $15,107,000 after acquiring an additional 308,753 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Evolus by 63.2% during the first quarter. Assenagon Asset Management S.A. now owns 710,713 shares of the company's stock worth $8,550,000 after acquiring an additional 275,260 shares in the last quarter. Frontier Capital Management Co. LLC purchased a new stake in shares of Evolus during the fourth quarter worth $2,648,000. Finally, Zimmer Partners LP raised its holdings in shares of Evolus by 66.6% during the fourth quarter. Zimmer Partners LP now owns 416,500 shares of the company's stock worth $4,598,000 after acquiring an additional 166,500 shares in the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Stock Performance

EOLS stock traded up $0.15 during trading on Friday, reaching $7.66. 534,857 shares of the stock were exchanged, compared to its average volume of 1,045,975. Evolus, Inc. has a twelve month low of $5.71 and a twelve month high of $17.82. The company has a market capitalization of $495.45 million, a P/E ratio of -7.82 and a beta of 1.07. The stock has a 50 day simple moving average of $8.26 and a 200-day simple moving average of $10.13. The company has a current ratio of 2.27, a quick ratio of 1.86 and a debt-to-equity ratio of 22.00.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Wall Street Zen lowered Evolus from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. HC Wainwright lowered their price target on Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Needham & Company LLC reissued a "hold" rating and set a $22.00 target price on shares of Evolus in a research report on Wednesday, August 6th. Finally, BTIG Research decreased their target price on Evolus from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $21.25.

Insider Buying and Selling

In other Evolus news, insider David Moatazedi sold 16,582 shares of Evolus stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.89, for a total transaction of $163,995.98. Following the sale, the insider directly owned 364,927 shares of the company's stock, valued at approximately $3,609,128.03. The trade was a 4.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brady Stewart acquired 30,000 shares of the firm's stock in a transaction on Friday, August 15th. The shares were bought at an average cost of $6.82 per share, for a total transaction of $204,600.00. Following the completion of the acquisition, the director directly owned 88,629 shares of the company's stock, valued at approximately $604,449.78. This represents a 51.17% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 133,627 shares of company stock valued at $1,325,764 over the last ninety days. Company insiders own 6.10% of the company's stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.